Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Gore

Showing results (21-30 of 215) with videos related to

Pageof 22
Sort By:
Seminars in Hematology|January 9, 2008
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromesElizabeth A Griffiths, Steven D Gore
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2014
New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approachAmer M Zeidan, Steven D Gore
Expert Opinion on Emerging Drugs|August 9, 2005
Emerging drugs for the treatment of myelodysplastic syndromePhilip J Nivatpumin, Steven D Gore
Oncology (Williston Park, N.Y.)|July 2, 2011
Myelodysplastic syndromes: where do we go from here?Hetty E Carraway, Steven D Gore
Leukemia & Lymphoma|February 2, 2022
Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesisRory M Shallis, Steven D Gore
Nature Reviews. Drug Discovery|November 23, 2006
DecitabineSteven D Gore, Carole Jones, Peter Kirkpatrick
Cancer Control : Journal of the Moffitt Cancer Center|December 17, 2009
Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromesSteven D Gore, Evelyn R Hermes-DeSantis
Cancer Control : Journal of the Moffitt Cancer Center|October 18, 2008
Future directions in myelodysplastic syndrome: newer agents and the role of combination approachesSteven D Gore, Evelyn R Hermes-DeSantis
Blood Reviews|August 20, 2013
Current therapy of myelodysplastic syndromesAmer M Zeidan, Yuliya Linhares, Steven D Gore
Expert Review of Hematology|September 3, 2013
Iron chelation therapy in myelodysplastic syndromes: where do we stand?Mhairi Mitchell, Steven D Gore, Amer M Zeidan
Pageof 22

Showing results (21-30 of 215) with videos related to

Sort By:
Pageof 22
Seminars in Hematology|January 9, 2008
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromesElizabeth A Griffiths, Steven D Gore
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2014
New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approachAmer M Zeidan, Steven D Gore
Expert Opinion on Emerging Drugs|August 9, 2005
Emerging drugs for the treatment of myelodysplastic syndromePhilip J Nivatpumin, Steven D Gore
Oncology (Williston Park, N.Y.)|July 2, 2011
Myelodysplastic syndromes: where do we go from here?Hetty E Carraway, Steven D Gore
Leukemia & Lymphoma|February 2, 2022
Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesisRory M Shallis, Steven D Gore
Nature Reviews. Drug Discovery|November 23, 2006
DecitabineSteven D Gore, Carole Jones, Peter Kirkpatrick
Cancer Control : Journal of the Moffitt Cancer Center|December 17, 2009
Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromesSteven D Gore, Evelyn R Hermes-DeSantis
Cancer Control : Journal of the Moffitt Cancer Center|October 18, 2008
Future directions in myelodysplastic syndrome: newer agents and the role of combination approachesSteven D Gore, Evelyn R Hermes-DeSantis
Blood Reviews|August 20, 2013
Current therapy of myelodysplastic syndromesAmer M Zeidan, Yuliya Linhares, Steven D Gore
Expert Review of Hematology|September 3, 2013
Iron chelation therapy in myelodysplastic syndromes: where do we stand?Mhairi Mitchell, Steven D Gore, Amer M Zeidan
Pageof 22